List view / Grid view
Product recalls due to contamination issues can be extremely costly for companies, in addition to the associated health implications. In this article, Marc Baiget Francesch explores the potential risks associated with N-nitrosodimethylamine (NDMA) contamination, why is it such a frequent contaminant and how to detect and eliminate the risks.
Farxiga (dapagliflozin) has been given Fast Track designation by the FDA to reduce the risk of cardiovascular death.
FDA is 'deeply concerned' about a third type of nitrosamine impurity detected in angiotensin II receptor blocker (ARB) medicines...
A tiny microneedle patch could be the future of delivering therapeutic cell related drugs to the heart of patients after a heart attack...
The FDA has provided guidance on valsartan recalls that have been occuring recently, providing lists of drugs affected, and methods of impurity testing...
Some drugs with active ingredient valsartan have been recalled due to presence of impurity NMDA...
A drug currently in trials for Parkinson's disease has shown promise in treating heart failure, without the risk of dangerous side effects...
Researchers have found that incorporating imaging technologies more precisely can predict heart attack risk...
Researchers assess aspirin as a preventive measure for patients who have both diabetes and heart failure...
The heart failure space across the seven key markets of the US, France, Germany, Italy, Spain, the UK and Japan is set to grow from $3.7 billion in 2016 to around $16.1 billion by 2026, representing an impressive compound annual growth rate of 15.7%, according to research and consulting firm…
24 May 2017 | By Niamh Marriott, Junior Editor
AstraZeneca has entered into an agreement with Recordati for the commercial rights to Seloken/Seloken ZOK treatments in Europe...
5 September 2016 | By Eppendorf
Within the EU Research and Innovation program Horizon 2020 the European Union is now funding the TECHNOBEAT research project with almost 6 million Euro...
4 May 2016 | By Victoria White, Digital Content Producer
The heart failure treatment market is set to rise from around $3.2 billion in 2015 to $11.8 billion by 2025, according to research and consulting firm GlobalData.
27 April 2016 | By Victoria White, Digital Content Producer
The National Institute for Health and Care Excellence (NICE) has recommended Novartis’ Entresto (sacubitril valsartan) for some people with heart failure.
19 April 2016 | By Victoria White, Digital Content Producer
Boehringer Ingelheim and Lilly have announced plans to conduct two trials investigating Jardiance for the treatment of people with chronic heart failure...
